{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:53:11Z","timestamp":1793055191929,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/mbc.0000000000000280","type":"journal-article","created":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T14:56:38Z","timestamp":1424271398000},"page":"403-407","source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2013utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever"],"prefix":"10.1097","volume":"26","author":[{"given":"Cho","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Wah","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyan","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirom","family":"Kamolratankul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1365-3156.2006.01678.x","article-title":"Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever.","volume":"11","author":"Bandyopadhyay","year":"2006","journal-title":"Trop Med Int Health"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/341410","article-title":"Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnam children with dengue shock syndrome.","volume":"35","author":"Willis","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R6-8-20210203","first-page":"682","article-title":"Abdel-Latif Mel-A, Goh AY, Chan PW, Lam SK.","volume":"143","author":"Lum","year":"2003","journal-title":"Preventive transfusion in dengue shock syndrome-is it necessary J Pediatr"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1086\/597773","article-title":"Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection.","volume":"48","author":"Lye","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00001721-200406000-00008","article-title":"The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome.","volume":"15","author":"Chuansumrit","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.mbc.0000186837.78432.2f","article-title":"Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.","volume":"16","author":"Chuansumrit","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/SLA.0b013e318176c4ec","article-title":"Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials.","volume":"248","author":"Hsia","year":"2008","journal-title":"Ann Surg"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials.","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"key":"R12-8-20210203","first-page":"68","article-title":"Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.","volume":"68","author":"Levi","year":"2010","journal-title":"Neth J Med"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.","volume":"295","author":"OConnell","year":"2006","journal-title":"JAMA"},{"key":"R14-8-20210203","first-page":"8","article-title":"Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.","volume":"19","author":"Kissela","year":"2008","journal-title":"BMC Neurol"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"862","DOI":"10.4269\/ajtmh.2008.78.862","article-title":"Quality of life of dengue patients.","volume":"78","author":"Lum","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4269\/ajtmh.2012.12-0019","article-title":"Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia.","volume":"87","author":"Shepard","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","article-title":"Calculating QALYs, comparing QALY and DALY calculations.","volume":"21","author":"Sassi","year":"2006","journal-title":"Health Policy Plann"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4269\/ajtmh.2005.72.786","article-title":"Economic impact of dengue feverdengue hemorrhagic fever in Thailand at the family and population levels.","volume":"72","author":"Clark","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","article-title":"An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine.","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2710.2008.01005.x","article-title":"Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature.","volume":"34","author":"Lindell-Osuagwu","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2005.01075.x","article-title":"HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry.","volume":"11","author":"Parameswaran","year":"2005","journal-title":"Haemophilia"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V95.4.1330.004k28_1330_1335","article-title":"Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.","volume":"95","author":"van t Veer","year":"2000","journal-title":"Blood"},{"key":"R25-8-20210203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0037-1963(01)90140-4","article-title":"The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.","volume":"38","author":"Hoffman","year":"2001","journal-title":"Semin Hematol"},{"key":"R26-8-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2516.2008.01969.x","article-title":"A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minormoderate bleeding episodes for haemophilia patients with inhibitors.","volume":"15","author":"Knight","year":"2009","journal-title":"Haemophilia"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.athoracsur.2006.10.033","article-title":"Recombinant activated factor VII in cardiac surgery: a systematic review.","volume":"83","author":"Warren","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R28-8-20210203","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MBC.0b013e3283389500","article-title":"Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients.","volume":"21","author":"Chuansumrit","year":"2010","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:23:13Z","timestamp":1620958993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-201506000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000280","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}